Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life.

ABSTRACT:

Background

Treatment and prophylaxis options for neonatal HIV are limited. This study aimed to develop a population pharmacokinetic model to characterize the disposition of maraviroc in neonates to inform dosing regimens and expand available options.

Methods

Using maraviroc concentrations from neonates who received either a single dose or multiple doses of 8 mg/kg of maraviroc in the first 6 weeks of life, a population pharmacokinetic model was developed to determine the effects of age, sex, maternal efavirenz exposure and concomitant ARV therapy on maraviroc disposition. The final model was used in Monte Carlo simulations to generate expected exposures with recommended dosing regimens.

Results

A total of 396 maraviroc concentrations, collected in the first 4 days of

SUBMITTER: Liyanage M 

PROVIDER: S-EPMC9560968 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature